Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.   AVT02 is a mAb biosimilar to AbbVie’s Humira, which is a leading drug indicated for the treatment of several autoimmune diseases, including, but not limited to, rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. It neutralizes the tumor necrosis alpha (TNF-α) involv...